 |
2 Diseases |  |
2 Trials |
|
2 Trials |  |
202 News |  |
| «1234» |
- |||||| lanifibranor (IVA337) / Inventiva
Clinical, P2b data: Hot off the press🔥study in @NEJM by @FrancqueSven, @Duke_liverdoc et al Pan-PPAR agonist #Lanifibranor in NASH 🔷Phase 2b, double-blind, RCT 🔷247 pt w/biopsy-confirmed, noncirrhotic, active NASH 🔷Lanifibranor 💊(800 mg or 1200 mg) vs. placebo x24 wks Results👇 #LiverTwitter (Twitter) - Oct 22, 2021
- lanifibranor (IVA337) / Inventiva
[VIRTUAL] TREATMENT RESPONSE TO THE PAN-PPAR AGONIST LANIFIBRANOR IN THE NATIVE STUDY: NASH RESOLUTION AND FIBROSIS IMPROVEMENT ARE CORRELATED () - Oct 21, 2021 - Abstract #AASLD2021AASLD_2160;
With lanifibranor 800 mg or 1200 mg, NASH resolution responders are significantly more likely to also be fibrosis improvers than non-responders; this correlation was also evident between ballooning improvement and fibrosis improvement for both lanifibranor doses. These analyses support a biologically plausible link between NASH resolution and fibrosis, which warrants further study.
- Aramchol (arachidyl amido cholanoic acid) / Galmed, Weizmann Institute of Science, resmetirom (MGL-3196) / Madrigal Pharma, lanifibranor (IVA337) / Inventiva
[VIRTUAL] PHYSICIAN AWARENESS OF AND PREFERENCES FOR COMBINATION THERAPY FOR NAFLD/NASH TREATMENT () - Oct 21, 2021 - Abstract #AASLD2021AASLD_2152;
Nevertheless, the stages of NAFLD/NASH suggest that treating multiple facets of the disease may be required . Hepatologists appear more aware and accepting than gastroenterologists of the potential for combination therapy in NAFLD/NASH .
- lanifibranor (IVA337) / Inventiva
[VIRTUAL] LANIFIBRANOR TREATMENT IMPROVES HEPATIC STEATOSIS IN PATIENTS WITH NASH, EVALUATED BY HISTOLOGICAL GRADING AND CONTROLLED ATTENUATION PARAMETER (CAP) () - Oct 21, 2021 - Abstract #AASLD2021AASLD_2143;
Histological steatosis grading showed a good correlation with CAP by FibroScan in the NATIVE study . Changes in CAP over time also correlated with changes in histological grading of steatosis as well as with improvements of markers of glucose and lipid metabolism .
- lanifibranor (IVA337) / Inventiva
[VIRTUAL] LANIFIBRANOR REVERSES FASTING GLUCOSE LEVELS TO NORMOGLYCEMIA IN PREDIABETIC PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH). () - Oct 21, 2021 - Abstract #AASLD2021AASLD_2142;
The effect size on reversal to normoglycemia and improvement of insulin resistance suggest a therapeutic benefit of Lanifibranor on glucose metabolism in prediabetic patients that warrants further study . These data also further support the relevance of screening patients with NASH for both overt T2D and prediabetes .
- lanifibranor (IVA337) / Inventiva
[VIRTUAL] LANIFIBRANOR IMPROVES NASH, FIBROSIS AND DIASTOLIC DYSFUNCTION IN A HAMSTER PRECLINICAL MODEL OF DIET INDUCED NASH () - Oct 21, 2021 - Abstract #AASLD2021AASLD_2141;
Lanifibranor also markedly and significantly improved DD similarly to pioglitazone. Activation of PPARγ is therefore sufficient to correct the DD in this model.
- lanifibranor (IVA337) / Inventiva
[VIRTUAL] LIVER SINUSOIDAL ENDOTHELIAL CELL (LSEC) CAPILLARIZATION IN NASH AND ITS EVOLUTION FOLLOWING LANIFIBRANOR TREATMENT: AN EXPLORATORY STUDY OF THE NATIVE CLINICAL TRIAL () - Oct 21, 2021 - Abstract #AASLD2021AASLD_2096;
Lanifibranor treatment is associated with a dose dependent reduction of CD34 staining which reached significance in periportal area. Whether this effect of lanifibranor is due to a direct effect on endothelial cells or a consequence of its anti-inflammatory and anti-fibrotic activity will require further studies.
- |||| lanifibranor (IVA337) / Inventiva
في دراسة مبشرة نشرت اليوم في @NEJM علاج لانيفيبرانور lanifibranor حسن من دهون الكبد وخفف من خشونة الكبد وقد يكون أحد العلاجات التي نستخدمها بإذن الله في المستقبل بعد إكتمال كل الدراسات عليه Lanifibranor in NASH الدكتور @AlkhouriNaim أحد المشاركين بالدراسة 👍 #livertwitter (Twitter) - Oct 21, 2021
- ||||| lanifibranor (IVA337) / Inventiva
Clinical: Honored to be able to work @FrancqueSven, outstanding investigators and @InventivaPharma on the lanifibranor trial for NASH—NASH resolution and fibrosis improvement in 24 wks! Particular to our patients for moving the field forward. My first in NEJM🎉@Duke_GI_ @AASLDtweets (Twitter) - Oct 21, 2021
- ||| lanifibranor (IVA337) / Inventiva
Management options for nonalcoholic steatohepatitis are limited. Lanifibranor showed promise against markers of NASH activity in preclinical studies, but its efficacy remained unknown. https://t.co/BEqOjpvqtp (Twitter) - Oct 21, 2021
- ||||| lanifibranor (IVA337) / Inventiva
Clinical: Great news for patients with active NASH! ✔️🔉🎉 #NATIVEstudy Lanifibranor , a pan-PPAR agonist, can decrease at least 2 points in the SAF-A score without worsening of fibrosis. @Duke_liverdoc Dr.Abdelmalek @Duke_GI_ @IMResidencyDuke #TheNewEnglandJournalofMedicine (Twitter) - Oct 21, 2021
- ||||| lanifibranor (IVA337) / Inventiva
Clinical: A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH https://t.co/LGOcIwL3IG (Twitter) - Oct 20, 2021
- ||||| lanifibranor (IVA337) / Inventiva
Clinical: A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH | NEJM https://t.co/AV7WWrjiZP (Twitter) - Oct 20, 2021
- |||| efruxifermin (AKR-001) / Amgen, lanifibranor (IVA337) / Inventiva
MORE: https://t.co/tfO3g8dXra #89bio @akerolabs @bmsnews #efruxifermin #Elastography #lanifibranor #MRIPDFF #NAFLD #NASH #noninvasivelivertesting #Semaglutide @MayoClinic Dr. @AlinaAllenMD #Histopathology @NaturePortfolio (Twitter) - Sep 30, 2021
- || lanifibranor (IVA337) / Inventiva
Clinical, Journal: A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study. (Pubmed Central) - Sep 26, 2021
P2b
Summary This study will evaluate the efficacy of a 24-week treatment of NASH with lanifibranor based on histological evaluations (SAF score) by biopsy. The number of responders according to the SAF Activity score-based definition from baseline to 24 weeks will be compared between groups and serves as primary endpoint.
- || Victoza (liraglutide) / Novo Nordisk, Ocaliva (obeticholic acid) / Intercept, lanifibranor (IVA337) / Inventiva
Retrospective data, Review, Journal: Systematic review and network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. (Pubmed Central) - Sep 19, 2021
These data provide relative rank-order efficacy of various NASH therapies in terms of their improvements in liver fibrosis and NASH resolution. Therapies that have been shown to improve NASH resolution may be combined with therapies that have an antifibrotic effect to further boost treatment response rate in future.
- |||||| lanifibranor (IVA337) / Inventiva, Hepalys Pharma
Enrollment open: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (clinicaltrials.gov) - Aug 16, 2021
P3, N=2000, Recruiting, Sponsor: Inventiva Pharma
Therapies that have been shown to improve NASH resolution may be combined with therapies that have an antifibrotic effect to further boost treatment response rate in future. Not yet recruiting --> Recruiting
- || Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma
Review, Journal: An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years. (Pubmed Central) - Jul 1, 2021
All these studies offer a real hope for SSc patients. The future challenges will be to customize patient-specific therapeutics with the goal to develop precision medicine for SSc.
- |||| lanifibranor (IVA337) / Inventiva
Preclinical: @EASL #ILC2021 has started. Visit our e-poster and ask questions to our team. #Lanifibranor #ACC #fibrosis #steatohepatitis #liverdisease #preclinicalresearch #biotechnologyindustry (Twitter) - Jun 23, 2021
- || Review, Journal: Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. (Pubmed Central) - May 15, 2021
While several promising drug candidates failed in phase 2 or 3 clinical trials (including elafibranor, emricasan and selonsertib), promising results with the farnesoid X receptor agonist obeticholic acid, the pan-PPAR agonist lanifibranor and the chemokine receptor CCR2/CCR5 inhibitor cenicriviroc support the expectation of an effective pharmacological therapy for liver fibrosis in the near future. Tackling NAFLD-associated fibrosis from different directions by combinatorial drug treatment and effective lifestyle changes hold the greatest prospects.
- |||||||||| lanifibranor (IVA337) / Inventiva, Hepalys Pharma
New P3 trial: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (clinicaltrials.gov) - Apr 18, 2021
P3, N=2000, Not yet recruiting, Sponsor: Inventiva Pharma
- lanifibranor (IVA337) / Inventiva
[VIRTUAL] Lanifibranor therapy improves markers of lipid metabolism, insulin resistance, liver injury and fibrosis in patients with NASH and F2 and F3 fibrosis stages: a subgroup analysis of the phase 2b NATIVE study () - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_910;
In patients with NASH and F2/F3 fibrosis, lanifibranor improved markers of lipid metabolism, IR, liver injury, inflammation and fibrosis at EOT compared to placebo, supporting previously reported histological efficacy. These findings support the planned phase3 studyof lanfibranor for patientswithNASHandF2-F3 fibrosis.
- lanifibranor (IVA337) / Inventiva
[VIRTUAL] The pan-PPAR agonist lanifibranor significantly improves cardiovascular risk biomarkers in patients with NASH () - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_909;
These data confirm the promising profile of lanifibranor for the treatment of NASH as a manifestation of the broader MS. These effects will be further evaluated in the planned phase 3 study in NASH patients with fibrosis F2/F3.
- seladelpar (MBX-8025) / CymaBay
[VIRTUAL] Effect of seladelpar and CB-0406 combination therapy on obesity, liver fibrosis and steatosis in a diet-induced obese (DIO) mouse model of biopsy-confirmed non-alcoholic steatohepatitis (NASH) with fibrosis (Poster area) - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_873;
The combination of seladelpar and CB-0406 in a mouse model of NASH led to substantially greater reductions in fibrosis and NASH than either monotherapy. This combination may offer a novel treatment option for patients with NASH.
- Firsocostat (GS-0976) / Gilead, lanifibranor (IVA337) / Inventiva
[VIRTUAL] Combination therapy of lanifibranor and firsocostat further improves steatohepatitis and fibrosis compared to monotherapy in a diet-induced murine model of NASH (Poster area) - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_870;
These data emphasize the complementary effect of these two compounds on lipids metabolic leading to further improvement of NASH and fibrosis. These data support the clinical investigation of a combination of lanifibranor and firsocostat in NASH patients.
- elafibranor (GFT505) / Genfit, lanifibranor (IVA337) / Inventiva
[VIRTUAL] Multicellular primary mouse liver spheroids for DILI, NAFLD, NASH and fibrosis studies (Poster area) - Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_743;
These data support the clinical investigation of a combination of lanifibranor and firsocostat in NASH patients. We established a robust multicellular in vitro spheroid culture model from primary mouse liver cells that can display a fibrotic response upon chronic exposure to APAP and under NASH conditions.
- ||| Lipaglyn (saroglitazar) / Zydus Cadila, lanifibranor (IVA337) / Inventiva
Clinical, P3 data: Congratulations on this important paper @NoureddinMD @IUGastro @ZydusUniverse . With saroglitazar being approved in India and lanifibranor in phase 3, the future looks 🌞@LiverArizona @Pinnacle_TX @GlobalLiver @schattenbergJ @Duke_liverdoc @MonicaTincopa (Twitter) - Apr 4, 2021
- | lanifibranor (IVA337) / Inventiva, Hepalys Pharma
Trial completion date, Trial primary completion date: Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Mar 23, 2021
P2, N=44, Recruiting, Sponsor: University of Florida
We established a robust multicellular in vitro spheroid culture model from primary mouse liver cells that can display a fibrotic response upon chronic exposure to APAP and under NASH conditions. Trial completion date: Dec 2021 --> Apr 2022 | Trial primary completion date: Dec 2021 --> Apr 2022
- Ocaliva (obeticholic acid) / Intercept, aldafermin (NGM282) / NGM Biopharma, lanifibranor (IVA337) / Inventiva
[VIRTUAL] A SYSTEMATIC REVIEW AND NETWORK META ANALYSIS FOR COMPARING PHARMACOLOGICAL INTERVENTIONS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (DDW Virtual) - Mar 15, 2021 - Abstract #DDW2021DDW_2905;
These data have important implications for future choice of combination therapy. Therapies that have been shown to improve NASH resolution may be combined with therapies that have an anti-fibrotic effect to further boost treatment response rate in future.
- || lanifibranor (IVA337) / Inventiva
Starting now: "Lanifibranor" Presenter: Manal Abdelmalek, MD, MPH Rebuttal: Brent A. Tetri, MD Register to join >> https://t.co/NcX476qNvD @Duke_liverdoc @DukeMedSchool #NASHTAG2021 #Livertwitter (Twitter) - Mar 12, 2021
- lanifibranor (IVA337) / Inventiva
THE PAN-PPAR AGONIST LANIFIBRANOR REDUCES STEATOSIS, INFLAMMATION AND FIBROSIS AND IMPROVES NAFLD ACTIVITY SCORE AND FIBROSIS STAGE IN THE GAN DIET-INDUCED OBESE AND BIOPSYCONFIRMED MOUSE MODEL OF NASH () - Mar 11, 2021 - Abstract #NASHTAG2021NASH-TAG_100;
In agreement with clinical findings, lanifibranor significantly improved NAS and Fibrosis Stage. These findings further validate clinical translatability of the GAN DIO-NASH mouse model.
- elafibranor (GFT505) / Genfit, lanifibranor (IVA337) / Inventiva
[VIRTUAL] Multicellular primary mouse liver spheroids for DILI, MAFLD and fibrosis studies () - Feb 23, 2021 - Abstract #BWG2021BWG_12;
Moreover, this model faithfully represents characteristics of MAFLD. In addition, these primary liver spheroids can potentially be used to assess novel anti-fibrotic/MAFLD compounds and for the development of novel therapies.
- ||| lanifibranor (IVA337) / Inventiva, Hepalys Pharma
Enrollment change, Trial completion date, Trial primary completion date: Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Feb 4, 2021
P2, N=34, Recruiting, Sponsor: University of Florida
In addition, these primary liver spheroids can potentially be used to assess novel anti-fibrotic/MAFLD compounds and for the development of novel therapies. N=84 --> 34 | Trial completion date: Mar 2021 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- lanifibranor (IVA337) / Inventiva
Lanifibranor () - Jan 11, 2021 - Abstract #NASHTAG2021NASH-TAG_6;
- || elafibranor (GFT505) / Genfit, aldafermin (NGM282) / NGM Biopharmaceuticals, lanifibranor (IVA337) / Inventiva
https://t.co/IjE3pZWiYy #AASLD #AkeroTherapeutics #aldafermin #cirrhosis #DigitalHealth #DrugTrial #EASL #EchoSens #efruxifermin #elafibranor #Elastography #FattyLiver #FDA #FGF21 #FIB4 #FibroScan #ILC2020 #InterceptPharmaceuticals #inventiva #lanifibranor #LeanNASH #Madrigal (Twitter) - Dec 24, 2020
- ||| https://t.co/FCdy5gVf4h #AASLD #TLMdX #Obesity #Diabetes #FattyLiver #NASH #NAFLD #dapagliflozin #saxagliptin @AstraZeneca #QTERN #licogliflozin #tropifexor @Novartis #lanifibranor #inventiva #elafibranor @genfit_pharma #obeticholicacid #OCA @InterceptPharma (Twitter) - Nov 19, 2020
- |||| lanifibranor (IVA337) / Inventiva
P3 data: Lanifibranor meets both primary FDA endpoints of NASH resolution and fibrosis regression. Exciting news for field of NASH. Onward to phase 3 trial. #TLMdX @AASLDtweets @Duke_GI_ @AmCollegeGastro @AmerGastroAssn, @DrLoomba @NoureddinMD, (Twitter) - Nov 15, 2020
- lanifibranor (IVA337) / Inventiva
[VIRTUAL] EFFECT OF THE PANPPAR AGONIST LANIFIBRANOR ON PLASMA BIOMARKERS OF LIVER NECRO- INFLAMMATION AND FIBROSIS IN NON-CIRRHOTIC NASH PATIENTS: ADDITIONAL RESULTS OF THE NATIVEPHASE 2b TRIAL. () - Nov 2, 2020 - Abstract #AASLD2020AASLD_2132;
N=84 --> 34 | Trial completion date: Mar 2021 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 Consistent with the histological data from the NATIVE study showing a decrease in the activity and fibrosis of the SAF score, the plasma markers of inflammation - ferritin and Hs-CRP, apoptosis - CK18-M30, and fibrosis - ro- C3, TMP1/MMP2, all show a statistically significant reduction in the lanifibranor treatment group compared to the placebo group.
- lanifibranor (IVA337) / Inventiva
[VIRTUAL] EFFICACY OF THE PANPPAR AGONIST LANIFIBRANOR ON THE HISTOLOGICAL ENDPOINTS NASH RESOLUTION AND FIBROSIS REGRESSION IS SIMILAR IN TYPE-2 DIABETIC AND NON-DIABETIC PATIENTS:ADDITIONAL RESULTS OF THE NATIVE PHASE 2b TRIAL IN NON-CIRRHOTIC NASH () - Nov 2, 2020 - Abstract #AASLD2020AASLD_2105;
Furthermore, clinically significant improvements in glucose and lipid metabolism were already observed after 4 weeks. Lanifibranor is hence a promising drug for NASH treatment in both non-diabetic and diabetic patients.
- ||||| lanifibranor (IVA337) / Inventiva
Breakthrough therapy designation: Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH https://t.co/QkHslVWgph @Duke_liverdoc @DrLoomba @NoureddinMD (Twitter) - Oct 13, 2020
- lanifibranor (IVA337) / Inventiva
[VIRTUAL] SELECTION BASED ON SAF ACTIVITY SCORE, NOT NASH CRN NAFLD ACTIVITY SCORE, LEADS TO SELECTION OF A PATIENT COHORT WITH MORE SEVERE NASH WITH MORE ADVANCED FIBROSIS: EXPERIENCE FROM THE NATIVE PHASE 2b STUDY OF THE PANPPAR AGONIST LANIFIBRANOR () - Oct 11, 2020 - Abstract #AASLD2020AASLD_1696;
P2b
By using SAF A≥3 as inclusion criterion rather than NAS≥4, NATIVE selected a higher percentage of patients with severely active steatohepatitis associated with advanced fibrosis (although no a priori minimum fibrosis criterion was set). These results support the concept of deleting steatosis from a score of NASH activity in order to select the more severe patients for pharmacological treatment.
- lanifibranor (IVA337) / Inventiva
[VIRTUAL] THE PANPPAR AGONIST LANIFIBRANOR INDUCES BOTH RESOLUTION OF NASH AND REGRESSION OF FIBROSIS AFTER 24 WEEKS OF TREATMENT IN NON-CIRRHOTIC NASH: RESULTS OF THE NATIVE PHASE 2b TRIAL () - Oct 11, 2020 - Abstract #AASLD2020AASLD_12;
P2b
Most notably, lanifibranor also met the combined endpoint of resolution of NASH and concomitant regression of fibrosis. The favourable safety profile further places lanifibranor as a promising drug for NASH treatment.
- |||| lanifibranor (IVA337) / Inventiva
Clinical: Lanifibranor meets efficacy, safety endpoints in phase 2b NASH trial https://t.co/XFvQT6rLjG (Twitter) - Oct 10, 2020
- || Review, Journal: Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. (Pubmed Central) - Sep 19, 2020
Preclinical strategies and how refinement and optimization may improve PPAR-targeted anti-NASH drug testing are also discussed. Finally, potential caveats related to PPAR agonism in anti-NASH therapy are stipulated.
- || lanifibranor (IVA337) / Inventiva
Might not be a breakthrough, but decent chance to make it -> https://t.co/AimoejcFva. $IVA #lanifibranor #NASH (Twitter) - Jun 29, 2020
- || lanifibranor (IVA337) / Inventiva
$IVA lanifibranor result - great news for $ICPT also? (Twitter) - Jun 15, 2020
- ||| lanifibranor (IVA337) / Inventiva
Positive phase IIb trial for the pan-PPAR agonist lanifibranor: 49% decrease of at least 2 points in the SAF activity score vs 27% in pcb arm https://t.co/m0Q3qxXeJO @Duke_liverdoc @mromerogomez @DrLoomba (Twitter) - Jun 15, 2020
- Triglide (fenofibrate) / Vectura, Shionogi
[VIRTUAL] Efficacy and safety of an acetyl CoA carboxylase inhibitor are improved in combination with PPAR agonists in a dyslipidemic rat model (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1419;
However, while Feno and Ela improved efficacy of ACCi to reduce liver TG, Lani and Sela did not alter or worsened steatosis. These studies support the use of PPARα ag to improve efficacy and safety of FIR in NASH patients.
- |||| lanifibranor (IVA337) / Inventiva, Hepalys Pharma
Trial completion: NATIVE: Phase 2b Study in NASH to Assess IVA337 (clinicaltrials.gov) - Apr 15, 2020
P2b, N=247, Completed, Sponsor: Inventiva Pharma
These studies support the use of PPARα ag to improve efficacy and safety of FIR in NASH patients. Active, not recruiting --> Completed
- || Clinical, Review, Journal: Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. (Pubmed Central) - Feb 25, 2020
PPARγ agonist pioglitazone showed tremendous promises in many non-metabolic disorders like chronic kidney disease, depression, inflammation, and autoimmune diseases...Interestingly, dual- or pan-PPAR agonists, namely chiglitazar, saroglitazar, elafibranor, and lanifibranor, are gaining momentum with their optimistic outcomes in many diseases including type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease, and primary biliary cholangitis...We anticipate the future design of better PPAR modulators with minimal off-target effects, high selectivity, superior bioavailability, and pharmacokinetics. This will open new possibilities for PPAR ligands in medicine.